Shanghai Kaibao Pharmaceutical CO.,Ltd
SHZ: 300039.SZ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Yingbin Zhou
- Employees
- 1,325
- Headquarters
- Shanghai, China
- IPO year
- 2010
- Market cap
- CN¥6.1B
- Website
- https://www.xykb.com
Loading 300039…
Loading profile data…Frequently asked questions about 300039
What does Shanghai Kaibao Pharmaceutical CO.,Ltd (300039.SZ) do?
Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern Chinese medicines primarily in China. Its primary products include Tanreqing injection for the treatment of pneumonia, acute and chronic bronchitis, and upper respiratory tract infection; Tanreqing capsules that clears heat and detoxifies...
Where does 300039.SZ trade?
Shanghai Kaibao Pharmaceutical CO.,Ltd (300039.SZ) trades on the Shenzhen Stock Exchange.
What sector is 300039.SZ in?
Shanghai Kaibao Pharmaceutical CO.,Ltd (300039.SZ) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Shanghai Kaibao Pharmaceutical CO.,Ltd?
Yingbin Zhou is the chief executive officer of Shanghai Kaibao Pharmaceutical CO.,Ltd (300039.SZ).
Where is Shanghai Kaibao Pharmaceutical CO.,Ltd headquartered?
Shanghai Kaibao Pharmaceutical CO.,Ltd is headquartered in China.
Does 300039.SZ pay a dividend?
Yes — Shanghai Kaibao Pharmaceutical CO.,Ltd (300039.SZ) paid a trailing twelve-month dividend of CNY 0.13 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 300039.SZ go public?
Shanghai Kaibao Pharmaceutical CO.,Ltd (300039.SZ) completed its initial public offering in 2010.